Biometals and Their Therapeutic Implications in Alzheimer's Disease

Overview

Journal Neurotherapeutics

Specialty Neurology

Date 2014 Oct 31

PMID 25354461

Citations 54

Authors

Scott Ayton

Peng Lei

Ashley I Bush

Affiliations

Soon will be listed here.

Abstract

No disease modifying therapy exists for Alzheimer's disease (AD). The growing burden of this disease to our society necessitates continued investment in drug development. Over the last decade, multiple phase 3 clinical trials testing drugs that were designed to target established disease mechanisms of AD have all failed to benefit patients. There is, therefore, a need for new treatment strategies. Changes to the transition metals, zinc, copper, and iron, in AD impact on the molecular mechanisms of disease, and targeting these metals might be an alternative approach to treat the disease. Here we review how metals feature in molecular mechanisms of AD, and we describe preclinical and clinical data that demonstrate the potential for metal-based drug therapy.

Citing Articles

Iron accumulation/overload and Alzheimer's disease risk factors in the precuneus region: A comprehensive narrative review.

Mohammadi S, Ghaderi S, Fatehi F Aging Med (Milton). 2024; 7(5):649-667.

PMID: 39507230 PMC: 11535174. DOI: 10.1002/agm2.12363.

A cocktail of Cu- and Zn-peptoid-based chelators can stop ROS formation for Alzheimer's disease therapy.

Behar A, Maayan G Chem Sci. 2024; .

PMID: 39464602 PMC: 11503657. DOI: 10.1039/d4sc04313h.

Role of copper chelating agents: between old applications and new perspectives in neuroscience.

Leuci R, Brunetti L, Tufarelli V, Cerini M, Paparella M, Puvaca N Neural Regen Res. 2024; 20(3):751-762.

PMID: 38886940 PMC: 11433910. DOI: 10.4103/NRR.NRR-D-24-00140.

Iron and Targeted Iron Therapy in Alzheimer's Disease.

Wang J, Fu J, Zhao Y, Liu Q, Yan X, Su J Int J Mol Sci. 2023; 24(22).

PMID: 38003544 PMC: 10671546. DOI: 10.3390/ijms242216353.

New Hybrid Compounds Incorporating Natural Products as Multifunctional Agents against Alzheimer's Disease.

Ciccone L, Camodeca C, Tonali N, Barlettani L, Rossello A, Fruchart Gaillard C Pharmaceutics. 2023; 15(10).

PMID: 37896129 PMC: 10610016. DOI: 10.3390/pharmaceutics15102369.

References

Yan R, Bienkowski M, Shuck M, Miao H, Tory M, Pauley A . Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature. 1999; 402(6761):533-7. DOI: 10.1038/990107. View

Pedersen W, Fu W, Keller J, Markesbery W, Appel S, Smith R . Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol. 1998; 44(5):819-24. DOI: 10.1002/ana.410440518. View

Soragni A, Zambelli B, Mukrasch M, Biernat J, Jeganathan S, Griesinger C . Structural characterization of binding of Cu(II) to tau protein. Biochemistry. 2008; 47(41):10841-51. DOI: 10.1021/bi8008856. View

Mitchell R, Lee S, Simmons Z, Connor J . HFE polymorphisms affect cellular glutamate regulation. Neurobiol Aging. 2009; 32(6):1114-23. DOI: 10.1016/j.neurobiolaging.2009.05.016. View

Lewis J, Dickson D, Lin W, Chisholm L, Corral A, Jones G . Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001; 293(5534):1487-91. DOI: 10.1126/science.1058189. View

Grossi C, Francese S, Casini A, Rosi M, Luccarini I, Fiorentini A . Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis. 2009; 17(2):423-40. DOI: 10.3233/JAD-2009-1063. View

Crouch P, Hung L, Adlard P, Cortes M, Lal V, Filiz G . Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. Proc Natl Acad Sci U S A. 2009; 106(2):381-6. PMC: 2626711. DOI: 10.1073/pnas.0809057106. View

Villemagne V, Burnham S, Bourgeat P, Brown B, Ellis K, Salvado O . Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013; 12(4):357-67. DOI: 10.1016/S1474-4422(13)70044-9. View

Barnham K, Masters C, Bush A . Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov. 2004; 3(3):205-14. DOI: 10.1038/nrd1330. View

10.

Choi S, Choi K, Park Y, Cho H, Yang E, Park H . Clioquinol, a Cu(II)/Zn(II) chelator, inhibits both ubiquitination and asparagine hydroxylation of hypoxia-inducible factor-1alpha, leading to expression of vascular endothelial growth factor and erythropoietin in normoxic cells. J Biol Chem. 2006; 281(45):34056-63. DOI: 10.1074/jbc.M603913200. View

11.

LeVine 3rd H, Ding Q, Walker J, Voss R, Augelli-Szafran C . Clioquinol and other hydroxyquinoline derivatives inhibit Abeta(1-42) oligomer assembly. Neurosci Lett. 2009; 465(1):99-103. PMC: 2754118. DOI: 10.1016/j.neulet.2009.08.002. View

12.

Zhukareva V, Sundarraj S, Mann D, Sjogren M, Blenow K, Clark C . Selective reduction of soluble tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study. Acta Neuropathol. 2003; 105(5):469-76. DOI: 10.1007/s00401-002-0668-8. View

13.

Raman B, Ban T, Yamaguchi K, Sakai M, Kawai T, Naiki H . Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid {beta} peptide. J Biol Chem. 2005; 280(16):16157-62. DOI: 10.1074/jbc.M500309200. View

14.

Suh S, Jensen K, Jensen M, Silva D, Kesslak P, Danscher G . Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res. 2000; 852(2):274-8. DOI: 10.1016/s0006-8993(99)02096-x. View

15.

Shipton O, Leitz J, Dworzak J, Acton C, Tunbridge E, Denk F . Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J Neurosci. 2011; 31(5):1688-92. PMC: 3836238. DOI: 10.1523/JNEUROSCI.2610-10.2011. View

16.

Dixon S, Lemberg K, Lamprecht M, Skouta R, Zaitsev E, Gleason C . Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012; 149(5):1060-72. PMC: 3367386. DOI: 10.1016/j.cell.2012.03.042. View

17.

Wong B, Ayton S, Lam L, Lei P, Adlard P, Bush A . A comparison of ceruloplasmin to biological polyanions in promoting the oxidation of Fe(2+) under physiologically relevant conditions. Biochim Biophys Acta. 2014; 1840(12):3299-310. DOI: 10.1016/j.bbagen.2014.08.006. View

18.

Su X, Wu W, Huang Z, Hu J, Lei P, Yu C . Hydrogen peroxide can be generated by tau in the presence of Cu(II). Biochem Biophys Res Commun. 2007; 358(2):661-5. DOI: 10.1016/j.bbrc.2007.04.191. View

19.

Tanzi R, Gusella J, Watkins P, BRUNS G, St George-Hyslop P, Van Keuren M . Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science. 1987; 235(4791):880-4. DOI: 10.1126/science.2949367. View

20.

Di Vaira M, Bazzicalupi C, Orioli P, Messori L, Bruni B, Zatta P . Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes. Inorg Chem. 2004; 43(13):3795-7. DOI: 10.1021/ic0494051. View